No recent analyst price targets found for XRTX.
Latest News for XRTX
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, highlights recent peer-reviewed, independent, published research reports that expand current knowledge that genetic factors are linked…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for XRTX.
Senate Trading
No Senate trades found for XRTX.
U.S. House Trading
No House trades found for XRTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.